Trazodone - Solicitation

The Department of Defense, via DLA, is issuing solicitation SPE2D2‑26‑R‑0003 for the acquisition of pharmaceutical prime‑vendor products, primarily various strengths of trazodone tablets, to meet agency annual demand projections. Offerors must demonstrate compliance with FDA current Good Manufacturing Practice (cGMP) standards, provide a distinct eleven‑digit National Drug Code (NDC) for each product, and disclose whether they are the manufacturer (including full name and address of any foreign manufacturing facilities) or a distributor. All proposals must be submitted electronically through the Defense Logistics Agency Internet Bid Board System (DIBBS) as two separate volumes: a Non‑Price Proposal (including technical requirements, past performance, evaluation results, and award selection) and a Price Proposal, both in U.S. dollars. The contract will be awarded to the responsible offeror whose technically acceptable proposal yields the lowest evaluated aggregate price, in accordance with FAR 52.212‑2 and related evaluation clauses. The solicitation incorporates numerous FAR and DFARS clauses, including commercial and government entity code reporting, tax on foreign procurements, and DFARS 252.204‑7019 (NIST SP 800‑171 DOD assessment requirements). Offerors must also meet the documentation requirements of FAR 52.212‑1 (SF 1449 and supporting pages) and provide required past‑performance data. Submissions via email, postal mail, or physical delivery are prohibited, and offers not in U.S. currency will be rejected. Compliance with the listed provisions and accurate completion of all required DIBBS fields are critical for eligibility.

Notice ID

891e9005252e4bbc9fe331ff38e80773

Solicitation Number

SPE2D2-26-R-0003

NAICS Code

325412

Classification Code

6505